EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

The slump has virtually wiped out several years of stellar gains that came after Novo’s Wegovy drug was approved as a ...

Today, the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, issued a positive opinion for a ...

How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average ...

Novo Nordisk's 7.2 mg Wegovy injectable aims to enhance chronic weight management in adults with obesity, using an expedited FDA review process. The Phase III STEP UP trial showed semaglutide 7.2 mg's ...

Novo Nordisk's Wegovy consumption jumped 70% after price cuts, lifting share in November. Eli Lilly's Mounjaro still led anti ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.